Michael Donegan's Insider Trades & SAST Disclosures
Michael Donegan's most recent trade in TherapeuticsMD Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on April 12, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Donegan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2023 | 50,000 | 61,853 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2023 | 50,000 | 0 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2023 | 2,400 | 0 | - | - | Performance Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2023 | 2,400 | 10,010 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2023 | 2,400 | 12,410 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2023 | 2,400 | 0 | - | - | Performance Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Sale of securities on an exchange or to another person at price $ 5.08 per share. | 26 Jan 2023 | 1,648 | 11,902 (0%) | 0% | 5.1 | 8,371 | Common Stock |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2023 | 1,140 | 13,550 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2023 | 1,140 | 0 | - | - | Performance Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Sale of securities on an exchange or to another person at price $ 5.08 per share. | 26 Jan 2023 | 49 | 11,853 (0%) | 0% | 5.1 | 249 | Common Stock |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 2,400 | 0 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 2,400 | 8,919 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Sale of securities on an exchange or to another person at price $ 5.34 per share. | 23 Jan 2023 | 1,302 | 7,617 (0%) | 0% | 5.3 | 6,950 | Common Stock |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 1,066 | 0 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 1,066 | 6,000 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 519 | 0 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 519 | 6,519 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 380 | 4,934 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 380 | 0 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | Prin. Fin. and Acctg. Officer | Sale of securities on an exchange or to another person at price $ 5.29 per share. | 23 Jan 2023 | 7 | 7,610 (0%) | 0% | 5.3 | 37 | Common Stock |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 120,000 | 120,000 | - | - | Performance Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 120,000 | 120,000 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 115,000 | 115,000 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 115,000 | 129,158 (0%) | 0% | - | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Sale of securities on an exchange or to another person at price $ 0.54 per share. | 30 Nov 2021 | 29,790 | 99,368 (0%) | 0% | 0.5 | 15,947 | Common Stock |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Other type of transaction at price $ 0.00 per share. | 29 Sep 2021 | 100,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Other type of transaction at price $ 0.00 per share. | 29 Sep 2021 | 100,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Other type of transaction at price $ 0.00 per share. | 29 Sep 2021 | 50,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Other type of transaction at price $ 0.00 per share. | 29 Sep 2021 | 40,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2021 | 38,954 | 38,954 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 160,000 | 160,000 | - | - | Performance Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 80,000 | 80,000 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 19,000 | 38,000 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2021 | 19,000 | 19,000 (0%) | 0% | - | Common Stock | |
| TherapeuticsMD Inc | Michael Donegan | CAO and VP Finance | Sale of securities on an exchange or to another person at price $ 1.04 per share. | 10 May 2021 | 4,842 | 14,158 (0%) | 0% | 1.0 | 5,036 | Common Stock |
| TherapeuticsMD Inc | Michael Donegan | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Nov 2020 | 230,000 | 230,000 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges